RP-185 Featured in 2018 AACR Presentation
April 18, 2018
SAN FRANCISCO, CA. – Riptide Bioscience’s lead drug candidate RP-185 was the subject of an invited poster presentation at this month’s annual meeting of the American Association for Cancer Research (AACR). The AACR meeting is the year’s premier venue for announcing the most significant new research into the etiology and treatment of cancer.
The title of the presentation was: “Novel Synthetic Peptide Targets CD206 Receptor Promoting Repolarization of Prostate Cancer TAMs, and Increases the Efficacy of Conventional Prostate Cancer Therapeutics.” It was authored by a team of scientists represented by Ahmad Bin Salam, MD, MS, from the Tuskegee University Center for Cancer Research, which included scientists from Johns Hopkins University, the National Cancer Institute, and Riptide Bioscience.
The presentation included data demonstrating the strong correlation of CD206 expression with worsened survival among prostate cancer patients; a description of the joint academic/commercial/government program to develop an engineered peptide therapeutic targeting CD206; and the dramatic results from application of RP-185 in animal models of melanoma, breast cancer, and metastatic prostate cancer.
Dr. Ahmad concluded, “This novel treatment repolarizes M2-like tumor-associated macrophages to a phagocytic M1-like phenotype, and shows promise to reverse the immunosuppressive tissue microenvironment in late stage prostate cancer.”
Riptide Bioscience, Inc., with laboratories in Vallejo, California, maintains an intensive program of research into peptide-based therapeutics. Contact: email@example.com